These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30888946)

  • 1. Tremfya™ (Guselkumab).
    Abramovits W; Wiqas A; Vincent KD; Versteeg SG; Gupta AK
    Skinmed; 2019; 17(1):36-38. PubMed ID: 30888946
    [No Abstract]   [Full Text] [Related]  

  • 2. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
    Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risankizumab (Skyrizi) for psoriasis.
    Med Lett Drugs Ther; 2019 Jun; 61(1573):81-83. PubMed ID: 31170118
    [No Abstract]   [Full Text] [Related]  

  • 4. Risankizumab for the treatment of psoriasis.
    Gu C; Yang J
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti IL-17 flared psoriasis in a patient on secukinumab.
    Noell C; McQuade B; Gottlieb A; Rosmarin D
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28547879
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
    Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
    Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis.
    Med Lett Drugs Ther; 2019 Jan; 60(1563):4-6. PubMed ID: 30681661
    [No Abstract]   [Full Text] [Related]  

  • 8. A safety evaluation of guselkumab for the treatment of psoriasis.
    Galluzzo M; D'Adamio S; Campione E; Bianchi L; Talamonti M
    Expert Opin Drug Saf; 2018 Jul; 17(7):741-751. PubMed ID: 29897790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
    Nemoto O; Hirose K; Shibata S; Li K; Kubo H
    Br J Dermatol; 2018 Mar; 178(3):689-696. PubMed ID: 29222947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atopic-like dermatitis after secukinumab injection: A case report.
    Burlando M; Cozzani E; Russo R; Parodi A
    Dermatol Ther; 2019 Jan; 32(1):e12751. PubMed ID: 30238583
    [No Abstract]   [Full Text] [Related]  

  • 11. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
    Zhuang Y; Calderon C; Marciniak SJ; Bouman-Thio E; Szapary P; Yang TY; Schantz A; Davis HM; Zhou H; Xu Z
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1303-1310. PubMed ID: 27515978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune hepatitis in two psoriasis patients treated with inflixmab.
    Goujon C; Dahel K; Bérard F; Guillot I; Gunera-Saad N; Nicolas JF
    J Am Acad Dermatol; 2010 Aug; 63(2):e43-4. PubMed ID: 20633783
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of infliximab in the treatment of psoriasis.
    Lee MR; Cooper AJ
    Australas J Dermatol; 2004 Aug; 45(3):193-5. PubMed ID: 15250904
    [No Abstract]   [Full Text] [Related]  

  • 14. Guselkumab (Tremfya) for psoriasis.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):179-180. PubMed ID: 29125591
    [No Abstract]   [Full Text] [Related]  

  • 15. Ustekinumab (Stelara) for psoriasis.
    Med Lett Drugs Ther; 2010 Jan; 52(1330):7-8. PubMed ID: 20208473
    [No Abstract]   [Full Text] [Related]  

  • 16. Moderate to severe plaque psoriasis - treatment with drugs of the classic scheme.
    Arnone M; Carvalho AVE; Takahashí MDF; Bernardo WM
    Rev Assoc Med Bras (1992); 2019 May; 65(4):530-534. PubMed ID: 31066805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guselkumab: First Global Approval.
    Markham A
    Drugs; 2017 Sep; 77(13):1487-1492. PubMed ID: 28819723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efalizumab-induced lupus-like syndrome.
    Durox H; Sparsa A; Loustaud-Ratti V; Prey S; Gondran G; Manea P; Vidal E; Bedane C
    Acta Derm Venereol; 2008; 88(3):270-1. PubMed ID: 18480928
    [No Abstract]   [Full Text] [Related]  

  • 19. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
    Dong J; Goldenberg G
    Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent angioedema associated with efalizumab.
    Mallbris L; von Bergen F; van Hage M; Ståhle M
    Acta Derm Venereol; 2009 Nov; 89(6):665-6. PubMed ID: 19997712
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.